BACKGROUND: Both genetics and the environment are implicated as risk factors for prostate cancer (PCa). This populationbased case--control study evaluated four single-nucleotide polymorphisms (SNPs) previously identified by genome-wide association studies to be associated with increased PCa susceptibility. Potential relationships between serum concentrations of phyto-estrogens and SNPs were also investigated. METHODS: Four SNPs (rs10993994, rs2660753, rs1016343 and rs6983267) were genotyped in 247 PCa patients, 125 BPH patients and 274 control men recruited in Scotland. Serum concentrations of the phyto-estrogens enterolactone, equol, genistein and daidzein were measured by isotope dilution gas chromatography--mass spectrometry. RESULTS: Increased PCa risk was associated with TT genotype of rs10993994 compared with CC and CT genotypes combined (odds ratio (OR) ¼ 1.87; 95% confidence interval (CI), 1.26--2.77). TT homozygotes who had low serum enterolactone concentrations (below median) were more likely to have PCa (OR ¼ 2.90; 95% CI, 1.28--6.57) than individuals with CC/CT genotype and high serum enterolactone concentrations (above median). PCa was not associated with the other three SNPs tested. CONCLUSIONS: PCa susceptibility was associated with TT genotype of SNP rs10993994 in this cohort of Scottish men and the increased risk of PCa was modified by serum enterolactone concentrations.
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed cancer in males in Scotland 1 and the UK. 2 Risk factors of PCa include age, ethnicity and family history. In a meta-analysis of familial PCa, a positive association was found between increased risk of PCa occurrence and having an affected first-degree relative, with a pooled relative risk of 2.5 (95% confidence interval (CI), 2.2--2.8). 3 It is believed that genetic factors contribute to PCa carcinogenesis, although few candidate genes have been validated across multiple populations. Large-scale genome-wide association studies (GWAS) typically examine thousands of single-nucleotide polymorphisms (SNPs) and compare their frequencies in cancer patients with those in control subjects. Various GWAS on PCa have been conducted in the UK, 4 ,5 USA 6 and Europe. 7 To date, these studies have identified a number of candidate SNPs associated with PCa susceptibility. Replication studies are now justified and can provide independent evidence to confirm the potential of using these candidate SNPs in identifying individuals at increased risk of PCa. In this replication study to confirm or refute findings previously reported in GWAS, we investigated the association of four SNPs identified in previous GWAS including rs10993994, 4 rs2660753, 4 rs1016343 5 and rs6983267 5 with PCa susceptibility in men in Scotland.
Besides family history and genetic factors, it is generally believed that the environment may also have a role in PCa susceptibility. In a study on Asian-Americans in the USA, it was found that the incidence of PCa was much higher in men born in the USA than their counterparts born in Asia. 8 The latter observation suggests that environmental factors such as diet or lifestyle characteristics may modify genetic susceptibility to PCa. Dietary phyto-estrogens are plant-derived compounds with structural and functional similarities to estradiol. In foodstuffs, the two main groups of phyto-estrogens are isoflavones (genistein, daidzein and equol) and lignans (enterolactone and enterodiol). In the European Prospective Investigation into Cancer and Nutrition Project, higher plasma concentrations of genistein were associated with lower risk of PCa. 9 By contrast, in the Prostate Cancer and Diet (PCANDIET) study PCa risk was negatively correlated with serum enterolactone concentrations but not equol, genistein or daidzein. 10 To date, it is not clear if pathways involving the four SNPs described above are related to the actions of dietary phyto-estrogens. In this study, we hypothesized that serum concentrations of phyto-estrogens might modify PCa risk in individuals carrying SNPs associated with increased PCa susceptibility.
The aim of this study was twofold. First, we investigated associations between PCa risk and four SNPs previously reported in GWAS to be relatively common (high minor allele frequency) and have relatively large odds ratios (ORs) (thus potential clinical significance). Second, the hypothesis that serum concentrations of phyto-estrogens might modify genetic susceptibility to PCa was tested.
MATERIALS AND METHODS
The Prostate Cancer and Diet (PCANDIET) study, details of which have previously been described, 10, 11 is a population-based case--control study on the relationship between PCa susceptibility, diet and genetic polymorphisms. Volunteers were recruited between 1998 and 2001. A consecutive series of newly diagnosed cases of primary PCa patients between 50 and 75 years of age were identified in collaboration with the urology clinics in Edinburgh and Glasgow and from the Scottish Cancer Registry. BPH patients attending the same clinics were also approached and community controls with no history of prostate diseases were selected using the Scottish Health Service routine computer procedures. Nonfasting blood specimens were collected with informed consent and approval from the local ethics committees. Serum specimens were stored at À70 1C before analysis of phyto-estrogen concentrations. Genomic DNA was extracted from whole blood using a Qiagen DNA extraction kit (Qiagen, Crawley, UK) and stored at À70 1C until analysis. For this replication study, remaining DNA samples from the PCANDIET study were available from 247 PCa patients, 125 BPH patients and 274 control men, aged 67.5 ± 5.4, 65.4 ± 5.7 and 66.9 ± 4.9, respectively (mean ± s.d.; P40.05). All subjects were Caucasian.
We searched the literature for GWAS on PCa susceptibility and SNPs using the following criteria to achieve a statistical power of 80%: (a) genome-wide association P value of o5 Â 10 À8 , (b) minor allele frequency of 40.1 based on the HapMap--CEU database and (c) OR of 41.5. Five SNPs from the literature fulfilled the above selection criteria including rs1016343, 5 rs2660753, 4 and rs6983267 5 rs7841060 6 and rs10993994. 4 Among these, rs7841060 was subsequently found to have no association with PCa risk in a meta-analysis, 12 and thus not tested in the present study. SNP genotyping was carried out using real-time PCR on StepOne Plus system (Applied Biosystems, Paisley, UK). Primers and probes for each SNP were custom made by Applied Biosystems. PCR amplification was performed using standard protocols. Genotype calling was manually performed based on the distribution of the three genotype cluster permutations.
Serum concentrations of four phyto-estrogens including the isoflavones genistein, daidzein and the daidzein metabolite equol and the lignan enterolactone were measured using isotope dilution gas chromatography--mass spectrometry as previously described. 13 The limits of detection for equol, enterolactone, daidzein and genistein were 0.417 nmol l À1 , 0.336 nmol l À1 , 0.394 nmol l À1 and 0.370 nmol l À1 , respectively. 14 Genotype and allele frequencies were calculated for each of the PCa, BPH and control groups. Frequencies of genotypes were compared using w 2 test for all SNPs except rs2660753 (Fisher's exact test) because of low prevalence of the minor allele in the latter. OR and their corresponding 95% CI were determined as per standard statistical methods. 15 The SPSS software version 20 (IBM SPSS, Chicago, IL, USA) was used for the Fisher's exact and Breslow--Day tests. All other statistical analyses were performed using Minitab Statistical Software version 14 (Minitab, State College, PA, USA). P values o0.05 are considered statistically significant. Table 1 summarizes characteristics including allele frequencies of the four SNPs genotyped in this study. In control subjects, genotype distributions of all four SNPs do not deviate from Hardy--Weinberg equilibrium (w 2 test, P40.05). Minor allele frequencies in controls are comparable with those previously reported by other studies on European populations (differences in minor allele frequency p0.02; Table 1 ). Also, distributions of genotypes of the four SNPs are not different between BPH patients and controls (P40.05; both w 2 and Fisher's exact tests); these two groups are combined in subsequent analyses to be compared with PCa cases.
RESULTS
Among the four SNPs tested, only rs10993994 was associated with PCa susceptibility in this replication study (Tables 2 and 3) . Compared with rs10993994 CC homozygotes, the TT genotype was associated with increased risk of PCa (OR ¼ 1.76; 95% CI, 1.13--2.73), whereas heterozygosity was not (OR ¼ 0.89; 95% CI, 0.62--1.29). Table 3 shows that TT homozygotes were more likely to have PCa than individuals with at least one C allele (CC or CT genotype), whereas increased risk of PCa could not be demonstrated when CT and TT genotypes were combined and then compared with CC homozygotes. 
DISCUSSION
Replication studies have an important role in the understanding of genetic associations reported in GWAS by either confirming such findings in other independent study populations or excluding potential false-positive associations. The present replication study was carried out to evaluate four SNPs reported by previous GWAS to be associated with PCa susceptibility in men of European descent. The lack of association between PCa and three of the SNPs examined (rs2660753, rs1016343 and rs6983267) was, although disappointing, not unexpected. Some previous replication studies on SNPs and PCa susceptibility have also reported low success rates of confirmation (o30%). 16--18 It is probable that the small sample size in this study may have missed true allelic differences between the controls and PCa cases (type-II error).
Among the four SNPs evaluated, only rs10993994 was found to be associated with increased PCa risk. At least two independent GWAS have identified rs10993994 allelic polymorphism as a PCa risk factor. 4, 19 Other replication studies have also confirmed an association between rs10993994 and increased PCa risk. 18, 20, 21 Our observations (Table 3) suggest that increased PCa risk associated with the minor allele (T) of rs10993994 is probably inherited in a recessive manner. Taken together, these findings support further exploratory studies using rs10993994 as a predictive genetic marker of PCa susceptibility in programs such as targeted screening for PCa in high-risk individuals or personalized PCa risk assessment.
The SNP rs10993994 maps to chromosome 10q11.2 and is located within a putative CREB-binding site of the microseminoprotein-beta (MSMB) gene promoter region. Compared with the PCa risk allele (T), the C allele within this putative CREB-binding site was shown to have stronger binding to the transcription factor CREB and higher MSMB promoter activity. 22 In recent studies, the risk allele of rs10993994 was associated with decreased expression of MSMB mRNA 23 and protein 24 in prostate tissues. Allelic polymorphism of rs10993994 was also shown to be a determinant of serum MSMB concentrations in PCa patients. 25 Whether decreased MSMB expression in the prostate due to the presence of rs10993994 PCa risk allele can lead to carcinogenesis is currently unclear. A conserved estrogen response element has been identified in the first intron of the MSMB gene. 26 Estrogen receptor-beta (ERb) was recently shown to upregulate the expression of MSMB, 27 and phyto-estrogens have been demonstrated to exhibit binding affinity and selectivity for estrogen receptorbeta. 28 Therefore, we hypothesized that serum concentrations of phyto-estrogens might influence PCa risk in individuals carrying the rs10993994 variant allele.
The observation that the highest PCa risk in this study was found in homozygotes of the rs10993994 PCa risk (T) allele with low serum enterolactone concentrations suggests a possible gene--environment interaction between the two risk factors. However, given that homogeneity of ORs could not be rejected using the Breslow--Day test, the high OR presented in Table 4B should be interpreted with caution. Serum enterolactone concentrations were, however, not different among the three rs10993994 genotypes (CC, CT and TT), indicating that rs10993994 genotype was unlikely to be a confounding factor for the association between PCa susceptibility and serum enterolactone concentrations. When stratified by enterolactone concentrations into two subgroups (4 median vs o median), the ORs associated with the TT genotype were 1.92 and 1.82, respectively (Supplementary Table 3 ), which were similar to the nonstratified OR of 1.87 associated with the TT genotype (Table 3A) . Likewise, stratification of PCa risk associated with low enterolactone concentrations by rs10993994 genotype into two subgroups (CC/CT vs TT) also resulted in ORs (1.59 and 1.51, respectively; data not shown) similar to the nonstratified OR of 1.56 (Table 4A) . Given these observations, the two risk factors of PCa susceptibility, that is, rs10993994 TT genotype and low serum enterolactone concentrations, were likely to be independent of each other in our study population. Data presented in Table 4B suggest that the combination of both risk factors confers higher PCa susceptibility than the individual risk factors alone.
The main limitation of this study is its relatively small sample size. Many of the genomic DNA samples from the original PCANDIET study are unfortunately no longer available. Although this replication study has demonstrated a statistically significant association between PCa susceptibility and rs10993994 only, the other three SNPs rs2660753, rs1016343 and rs6983267 need to be explored in further large-scale studies. For the assessment of the long-term intake of phyto-estrogens, there is no general consensus on the best type of clinical specimens (such as serum or urine) that should be taken, 29 and whether fasting samples are better than nonfasting ones. 30 Future studies on the intake and concentrations of phyto-estrogens are required to address this unresolved issue.
